To safely reduce the burden of therapy in children, adolescents and young adults with mature
B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT
Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and reducing the dose of anthracycline
(doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy
backbone (Immunochemotherapy).